Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875020 | 1.00 | C3AR1 (0.47) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL12222096 | 1.00 | C3AR1 (0.47) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL25148126 | 0.88 | SIRT5 (0.38) | C3AR1NOD1CTDSP1FOLH1ECE1 | |
| SCHEMBL24804881 | 0.88 | C3AR1 (0.49) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL29359380 | 0.87 | C3AR1 (0.46) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL16862613 | 0.87 | C3AR1 (0.46) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL6047671 | 0.87 | C3AR1 (0.46) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL28819908 | 0.87 | C3AR1 (0.46) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL16862522 | 0.87 | C3AR1 (0.46) | C3AR1NOD1CTDSP1FOLH1GNPAT | |
| SCHEMBL16801786 | 0.87 | C3AR1 (0.46) | C3AR1NOD1CTDSP1FOLH1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-11752214-B2 | Protein-antiviral compound conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230277682-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
| US-10624968-B2 | Compounds for treating cancer | Bicyclerd Limited (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20180208667-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2018-07-26 | — | — | US | disclosed |
| WO-2018115204-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2018-06-28 | — | — | WO | disclosed |
| US-9879086-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2018-01-30 | — | — | US | disclosed |
| US-20170247408-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-04-27 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20170043031-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-03-17 | — | — | US | disclosed |
| US-8580921-B2 | Protein nanorings | UNIVERSITY OF MINNESOTA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130059359-A1 | Protein Nanorings | UNIVERSITY OF MINNESOTA (US) | 2013-03-07 | — | — | US | disclosed |
| US-8236925-B1 | Protein nanorings | UNIVERSITY OF MINNESOTA (US) | 2012-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | C3AR1 4306/4885NOD1 3558/4885CTDSP1 1714/4885 |
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | C3AR1 3764/4885NOD1 4799/4885CTDSP1 225/4885 |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | C3AR1 589/4885NOD1 4056/4885CTDSP1 3247/4885 |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | AURKC, AURKA, EGFR | C3AR1 288/4885NOD1 4539/4885CTDSP1 2959/4885 |
| US-20170247408-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | C3AR1 3764/4885NOD1 4799/4885CTDSP1 225/4885 |
| US-20230277682-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | HAVCR2, VARS1, VIM | C3AR1 30/4885NOD1 1961/4885CTDSP1 1056/4885 |
| US-10624968-B2 | Compounds for treating cancer | TP53, VHL, MYC | C3AR1 4007/4885NOD1 4629/4885CTDSP1 2841/4885 |
| US-20170043031-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | C3AR1 351/4885NOD1 4495/4885CTDSP1 2824/4885 |
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | TP53, VHL, MYC | C3AR1 4007/4885NOD1 4629/4885CTDSP1 2841/4885 |
| US-11752214-B2 | Protein-antiviral compound conjugates | BMX, SARS1, VSIG8 | C3AR1 1360/4885NOD1 1448/4885CTDSP1 756/4885 |
| US-20180208667-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | C3AR1 3764/4885NOD1 4799/4885CTDSP1 225/4885 |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | C3AR1 4306/4885NOD1 3558/4885CTDSP1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.